Licensed from Tokyo Tanabe, Ltd., Survanta is a natural surfactant derived from bovine lungs. The drug is administered through a breathing tube into the lungs, replenishing the missing surfactant and allowing premature infants to breathe more normally.
As mentioned previously, Abbott tiled a U.S. NDA for the pediatric form of clanthromycin in 1992. The pediatric version is available in several major markets, including Japan and a number of countries in Europe.
TAP Pharmaceuticals Inc.
Abbott's joint venture with Takeda Chemical Industries, Ltd., of Japan, TAP Pharmaceuticals Inc., continues to achieve excellent growth.
Lupron Depot 75 mg., which is used for the palliative treatment of advanced prostate cancer, is in clinical trials to determine its effectiveness for

reducing the size of the prostate prior to radical prostatectomy.
Lupron Depot 3.75 mg. has achieved wide physician acceptance as a treatment tor endometriosis, a painful and chronic pelvic disease and a leading cause of infertility.
In August 1992, TAP filed an NDA in the United States for the use of Lupron Depot-PED for the treatment of precocious puberty.  Studies are also under way to evaluate the drug's effectiveness for the treatment of infertility, fibroid tumors, and as a surgical adjunct.
Clinical studies are being completed prior to filing a U.S. NDA for Prevactd (lansoprazole), a proton pump inhibitor. It is anticipated that the filing will include use in treating duodenal ulcers, gastric ulcers, reflux esophagitis and resistant reflux esophagitis.
Senora Santos, a nurse at Hospital la Pai (Hospital of Peace! in Madrid, receives once-a -month injections of leuprolide acetate as treatment for endometriosis. Sold as Ginecrin Depot in Spain and Lupron Depot in the United States, leuprolide is also indicated for the palliative treatment of advanced prostate cancer.

Chemical and Agricultural Products
The primary role of Abbott's chemical business is to supply bulk pharmaceuticals to both internal divisions and external customers.
The company's chemical and fermentation capabilities also support the division's agricultural products.
Abbott is the world's leading producer of biorational, or environmentally compatible, insecticides and plant-growth regulators, which include the larvicides DiPel and VectoBac and the plant-growth regulators Promalin, ProGibb, ProVide, Release and Ryzlip.
In 1992, a new biorational insecticide, XenTari, for control of armyworms and diamondback moths, was registered with the U.S. Environmental Protection Agency.
In the area of animal health, the company's two patented anti-infective products, difloxacin and sarafloxacin, have shown excellent performance in studies with animals and fish. In April 1992, Abbott filed for regulatory approval with the U.S. PDA for the use of sarafloxacin in chickens, turkeys and catfish. Under a licensing agreement with Abbott, Solvay et Cie of Belgium will market sarafloxacin and dirloxacm outside the United States.
Nutritional Products
Abbott's nutritional business includes total and supplemental nutritional products for infants, children and adults. Stimulating the growth of this business are expanding worldwide markets and Abbott's stream of new products formulated for the special nutritional needs created by specific diseases and patient conditions. In the U.S. pediatric nutntionals marketplace, the company continues to hold a leadership position with a full line of products for both routine and specialized infant feeding needs.